Treatment alternatives for spinal cord injury related spasticity

Journal of Spinal Cord Medicine

Volumn 22, Issue 3, 1999, Pages 199-217

  Kirshblum, Steven ^a,b  

^a KESSLER INSTITUTE FOR REHABILITATION   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Spasticity; Spinal cord injury

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CENTRAL MUSCLE RELAXANT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

DISABILITY; HUMAN; INTRASPINAL DRUG ADMINISTRATION; NERVE BLOCK; REVIEW; SPASTICITY; SPINAL CORD INJURY;

BACLOFEN; BOTULINUM TOXINS; DISABILITY EVALUATION; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; NERVE BLOCK; PARASYMPATHOLYTICS; SPINAL CORD INJURIES;

EID: 0033182093     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.1999.11719570     Document Type: Article

References (190)

1. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Chicago. Year Book Publishers, 1980. pp 485-494.
2. Katz RT, Rymer WZ. Spastic hypertonia: Mechanisms and measurement. Arch Phys Med Rehabil. 1989;70:144-155.
3. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl. 1997;6:S1-S13.
4. Young RR, Delwaide PJ. Drug therapy: Spasticity. N Engl J Med. 1981;304:28-33, 96-99.
5. Young RR. The physiology of spasticity and its response to therapy. Ann N Y Acad Sci. 1988;531:146-149.
6. Landau WM. Spasticity. What is it? What is it not? In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control, Chicago. Year Book Publishers. 1980. pp 17-24.
7. Young RR, Emre M, Nance PW, Schapiro R, Barnes M. Current issues in spasticity management. Neurologist. 1997;3:261-275.
8. Maynard FM, Karunas RS, Waring WP. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil. 1990;71:566-569.
9. Little JW, Micklesen P, Umlauf R, Britell C. Lower extremity manifestations of spasticity in chronic spinal cord injury. Am J Phys Med Rehabil. 1989;68:32-36.
10. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540-542.
11. Lee KG, Carson L, Kinnin E, Patterson V. The Ashworth scale: A reliable and reproducible method of measuring spasticity. J Neurol Rehab. 1989;3:205-209.
12. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987; 67:206-207.
13. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517-1521.
14. Pierson SH. Outcome measures in spasticity management. Muscle Nerve Suppl. 1997;6:S36-S60.
15. Katz RT, Rovai GP, Brait C, Rymer WZ. Objective quantification of spastic hypertonia: Correlation with clinical findings. Arch Phys Med Rehabil. 1992;73:339-347.
16. Wartenberg R. Pendulousness of the legs as a diagnostic test. Neurology. 1951;1:18-24.
17. Bajd T, Vodovnik L. Pendulum testing of spasticity. J Biomed Eng. 1984;6:9-16.
18. Bohannon RW. Variability and reliability of the pendulum test for spasticity using a Cybex II isokinetic dynamometer. Phys Ther. 1987;67:659-661.
19. Jamshidi M, Smith AW. Clinical measurement of spasticity using the pendulum test: Comparison of electrogoniometric and videotape analyses. Arch Phys Med Rehabil. 1996;77:1129-1132.
20. Priebe MM, Sherwood AM, Thornby JI, Kharas NF, Markowski J. Clinical assessment of spasticity in spinal cord injury: A multidimensional problem. Arch Phys Med Rehabil. 1996;77:713-716.
21. Ditunno JF Jr, Formal CS. Chronic spinal cord injury. N Engl J Med. 1994;330:550-556.
22. Matthews WB. Ratio of maximum H reflex to maximum M response as a measure of spasticity. J Neurol Neurosurg Psychiatry. 1966;29:201-204.
23. Delwaide PJ. Spinal reflex studies as a tool for clinical neuropharmacology. New Trends In Clinical Pharmacology. 1992;1:1-4.
24. Delwaide PJ. Electrophysiological testing of spastic patients: its potential usefulness and limitations. In: Delwaide PJ, Young RR, eds. Clinical neurophysiology in spasticity: Contribution to assessment and pathophysiology. Amsterdam: Elsevier; 1985:185-203.
25. Delwaide PJ. Human reflex studies for understanding the motor system. Phys Med Rehabil Clin North Am. 1993;4:669-686.
26. Burke D. Critical examination of the case for or against fusimotor involvement in disorders of muscle tone. Adv Neurol. 1983;39:133-150.
27. Ongerboer de Visser BW, Koelman IR, Bour LJ, Hilgevoord AA. Signs of the upper motoneuron syndrome in relation to soleus Hoffmann reflex tests. In: Thilmann AF, Burke DJ, Rymer WZ, eds. Spasticity: Mechanisms and management. Berlin: Springer Verlag; 1993:287-295.
28. Fisher MA. F/M ratios in polyneuropathy and spastic hyperreflexia. Muscle Nerve. 1998;11:217-222.
29. Eisen A, Odusote K. Amplitude of the F wave: A potential means of documenting spasticity. Neurology. 1979;29:1306-1309.
30. Eisen A. Electromyography in disorders of muscle tone. Can J Neurol Sci. 1987;14:501-505.
31. Merritt JL. Management of spasticity in spinal cord injury. Mayo Clin Proc. 1981;56:614-622.
32. Stolp-Smith KA, Wainberg MC. Antidepressant exacerbation of spasticity. Arch Phys Med Rehabil. 1999;80:339-342.
33. Guttman L. Spinal cord injury comprehensive management and research. Oxford, England: Blackwell Scientific; 1976.
34. Burke D, Andrews C, Ashby P. Autogenic effects of static muscle stretch in spastic man. Arch Neurol. 1971; 25:367-372.
35. Guissard N, Duchateau J, Hainaut K. Muscle stretching and motoneuron excitability. Eur J Appl Physiol. 1988;58:47-52.
36. Castellucci VF, Carew TJ, Kandel ER. Cellular analysis of long-term habituation of the gill-withdrawal reflex of Aplysia californica. Science. 1978;202:1306-1308.
37. Castellucci VF, Kandel ER. A quantal analysis of the synaptic depression underlying habituation of the gill-withdrawal reflex in Aplysia. Proc Natl Acad USA. 1974;71:5004-5008.
38. Hartviksen K. Ice therapy in spasticity. Acta Neurol Scand. 1962;38:79-84.
39. Miglietta O. Action of cold on spasticity. Am J Phys Med. 1973;52:198-205.
40. Price R, Lehmann JF, Boswell-Bessette S, Burleigh A, deLateur BJ. Influence of cryotherapy on spasticity at the human ankle. Arch Phys Med Rehabil. 1993;74:300-304.
41. Mills WJ, Pozos RS. A decrease in clonus amplitude by topical anesthesia. Electroencephalogr Clin Neurophysiol. 1985;61:509-518.
42. Franek A, Turczynski B, Opara J. Treatment of spinal spasticity by electrical stimulation. J Biomed Eng. 1988;10:266-270.
43. Stefanovska A, Rebersek S, Bajd T, Vodovnik L. Effects of electrical stimulation on spasticity. Crit Rev Phys Med Rehabil. 1991;3:59-99.
44. Pease WS. Therapeutic electrical stimulation for spasticity: quantitative gait analysis. Am J Phys Med Rehabil. 1998;77:351-355.
45. Robinson CJ, Kett NA, Bolam JM. Spasticity in spinal cord injured patients: 1. Short-term effects of electrical stimulation. Arch Phys Med Rehabil. 1988;69:598-604.
46. Rosche J, Paulus C, Maisch U, Kaspar A, Mauch E, Kornhuber HH. The effects of therapy on spasticity utilizing a motorized exercise-cycle. Spinal Cord. 1997;35:176-178.
47. Granat MH, Ferguson AC, Andrews BJ, Delargy M. The role of functional electrical stimulation in the rehabilitation of patients with incomplete spinal cord injury - observed benefits during gait studies. Paraplegia. 1993;31:207-215.
48. Bajd T, Gregoric M, Vodovnik L, Benko H. Electrical stimulation in treating spasticity resulting from spinal cord injury. Arch Phys Med Rehabil. 1985;66:515-517.
49. Goulet C, Arsenault AB, Bourbonnais D, Laramee MT, Lepage Y. Effects of transcutaneous electrical nerve stimulation on H-reflex and spinal spasticity. Scand J Rehabil Med. 1996;28:169-176.
50. Basmajian JV. Biofeedback in rehabilitation: A review of principles and practices. Arch Phys Med Rehabil. 1981;62:469-475.
51. Wolf SL, Binder-MacLeod SA. Electromyographic biofeedback applications to the hemiplegic patient. Changes in upper extremity neuromuscular and functional status. Phys Ther. 1983;63:1393-1403.
52. Wolf SL, Binder-MacLeod SA. Electromyographic biofeedback applications to the hemiplegic patient. Changes in lower extremity neuromuscular and functional status. Phys Ther. 1983;63:1404-1413.
53. Kunkel CF, Scremin AM, Eisenberg B, Garcia JF, Roberts S, Martinez S. Effect of "standing" on spasticity, contracture, and osteoporosis in paralyzed males. Arch Phys Med Rehabil. 1993;74:73-78.
54. Bohannon RW. Tilt table standing for reducing spasticity after spinal cord injury. Arch Phys Med Rehabil. 1993;74:1121-1122.
55. Booth BJ, Doyle M, Montgomery J. Serial casting for the management of spasticity in the head injured adult. Phys Ther. 1983;63:1960-1966.
56. Cherry DB, Weigand GM. Plaster drop-out casts as a dynamic means to reduce muscle contracture. Phys Ther. 1981;61:1601-1603.
57. Collins K, Oswald P, Burger G, Nolden J. Customized adjustable orthoses: Their use in spasticity. Arch Phys Med Rehabil. 1985;66:397-398.
58. Kaplan N. Effect of splinting on reflex inhibition and sensorimotor stimulation in treatment of spasticity. Arch Phys Med Rehabil. 1962;43:565-569.
59. McPherson JJ, Becker RH, Franszczak N. Dynamic splint to reduce the passive component of hypertonicity. Arch Phys Med Rehabil. 1985;66:249-252.
60. Davidoff RA. Antispasticity drugs: Mechanisms of action. Ann Neurol. 1985;17:107-116.
61. Katz RT. Management of spasticity. Am J Phys Med Rehabil. 1988;67:108-116.
62. Faigle JW. Chemistry and pharmacokinetics of baclofen. In: Feldman, RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago: Year Book Medical; 1980.
63. Duncan GW, Shahani BT, Young RR. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology. 1976;26:441-446.
64. Sachais BA, Logue JN, Carey MS. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol. 1977;34:422-428.
65. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. Br Med J. 1971;4:15-17.
66. Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago: Year Book Medical; 1980.
67. Koella WP. Baclofen: Its general pharmacology and neuropharmacology. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: disordered motor control. Chicago: Year Book Medical; 1980.
68. Khanna OP. Non-surgical therapeutic modalities. In: Krane RJ, Siroky MB, eds. Clinical neurology. Boston: Little Brown; 1979.
69. Roy CW, Wakefield IR. Baclofen pseudopsychosis: Case report. Paraplegia. 1986;24:318-321.
70. Sandyk R, Gillman MA. Baclofen-induced memory impairment. Clin Neuropharmacol. 1985;8:294-295.
71. Physicians' Desk Reference. Medical Economics Company Inc. Edition 51; 1997:847-848.
72. Kirkland LR. Baclofen dosage: A suggestion. Arch Phys Med Rehabil. 1984;65:214.
73. Bianchine JR. Drugs for Parkinson's Disease, spasticity, and acute muscle spasms. In: A.G. Gilmore, ed. The pharmacological bases of therapeutics, 7th ed. New York, NY: MacMillan; 1985:486-490.
74. Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol. 1981;38:588-589.
75. From A, Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand. 1975;51:158-166.
76. Roussan M, Terrence C, Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica. 1985;4:278-284.
77. Fromm GH, Terrence CF. Comparison of L-baclofen and racemic baclofen in trigeminal neuralgia. Neurology. 1987;37:1725-1728.
78. Sawynok J, Dickson C. D-Baclofen is an antagonist at baclofen receptors mediating antinociception in the spinal cord. Pharmacology. 1985;31:248-259.
79. Bormann J. Electrophysiology of GABAA and GABAB receptor subtypes. Trends Neurosci. 1988;11:112-116.
80. Costa E, Guidotti A. Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Phamacol Toxicol. 1979;19:531-545.
81. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6: S92-S120.
82. Corbett M, Frankel HL, Michaelis L. A double-blind, cross-over trial of Valium in the treatment of spasticity. Paraplegia. 1972;10:19-22.
83. Wilson LA, McKechnie AA. Oral diazepam in the treatment of spasticity in paraplegia a double-blind trial and subsequent impressions. Scott Med J. 1966;11:46-51.
84. Cook JB, Nathan PW. On the site of action of diazepam in spasticity in man. J Neurol Sci. 1967;5:33-37.
85. Tseng TC, Wang SC. Locus of action of centrally acting muscle relaxants, diazepam and tybamate. J Pharmacol Exp Ther. 1971;178:350-360.
86. Verrier M, Ashby P, MacLeod S. Diazepam effect on reflex activity in patients with complete spinal lesions and in those with other causes of spasticity. Arch Phys Med Rehabil. 1977;58:148-153.
87. Whyte J, Robinson KM. Pharmacologic management. In: Glenn MB, Whyte J, eds. The practical management of spasticity in children and adults. Philadelphia: Lea and Febiger; 1990:201-226.
88. Glenn MB. Update on pharmacology. J Head Trauma Rehabil. 1986;1:72-74.
89. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983;309:354-358, 410-416.
90. Basmajian JV, Shankardass K, Russel D, Yucel V. Ketazolam treatment for spasticity: Double-blind study of a new drug. Arch Phys Med Rehabil. 1984;65:698-701.
91. Basmajian JV, Shankardass K, Russel D. Ketazolam once daily for spasticity: Double-blind cross-over study. Arch Phys Med Rehabil. 1986;67:556-557.
92. Cendrowski W, Sobczyk W. Clonazepam, baclofen and placebo in the treatment of spasticity. Eur Neurol. 1977;16:257-262.
93. Herman R, Mayer N, Mecomber SA. Clinical pharmaco-physiology of dantrolene sodium. Am J Phys Med. 1972;51:296-311.
94. Van Winkle WB. Calcium release from skeletal muscle sarcoplasmic reticulum: site of action of dantrolene sodium. Science. 1976;193:1130-1131.
95. Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs. 1986;32:130-168.
96. Monster AW, Tamai Y, McHenry J. Dantrolene Sodium: Its effects on extrafusal muscle fibers. Arch Phys Med Rehabil. 1974;55:355-362.
97. Mai J, Pedersen E. Mode of action of dantrolene sodium in spasticity. Acta Neurol Scand. 1979;59:309-316.
98. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology. 1977;72:610-616.
99. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry. 1976;39:350-356.
100. Weiser R, Terenty T, Hudgson P, Weightman D. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner. 1978;221:123-127.
101. Tuckman J, Chu DS, Petrillo CR, et al. Clinical trial of alpha adrenergic receptor stimulating drug (Clonidine) for treatment of spasticity in spinal cord injury patients. In: Naftchi NE, ed. Spinal cord injury. New York: SP Medicine and Science Books; 1982:133-137.
102. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: A clinical trial. Arch Phys Med Rehabil. 1988;69:193-194.
103. Maynard FM. Early clinical experience with clonidine in spinal spasticity. Paraplegia. 1986;24:175-182.
104. Yablon SA, Sipski ML. Effect of transdermal clonidine on spinal spasticity. A case series. Am J Phys Med Rehabil. 1993;72:154-157.
105. Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc J. 1985;133:41-42.
106. Weingarden SI, Belen JG. Clonidine transdermal system for treatment of spasticity in spinal cord injury. Arch Phys Med Rehabil. 1992;73:876-877.
107. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994;44(Suppl 9):S60-S69.
108. Roberts RC, Part NJ, Pokorny R, Muir C, Leslie GC, Emre M. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology. 1994;44(Suppl 9):S29-S31.
109. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin. 1988;10:699-708.
110. Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci. 1988;15:15-19.
111. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44(Suppl 9): S34-S43.
112. Knutsson E, Martensson A, Gransberg L. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci. 1982;53:187-204.
113. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(Suppl 9):S70-S78.
114. Mathias CJ, Luckitt J, Desai P, Baker H, el Masri W, Frankel HL. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev. 1989;26:9-16.
115. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(Suppl 9):S44-S52.
116. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53:435-452.
117. Davies J, Johnston SE, Hill DR, Quinlan JE. Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurons to noxious peripheral stimuli by an action at alpha 2-adrenoreceptors. Neurosci Lett. 1984;48:197-202.
118. Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Reduction of centrally stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats. Arch Int Pharmacodyn Ther. 1985;277:321-327.
119. Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Influence of clonidine and a new related imidazoline derivative (tizanidine) on rat gastric mucosa. Pharmacology. 1986;32:109-113.
120. DeSarro GB, Croucher MJ, Meldrum BS. Anticonvulsant actions of DS 103-282. Pharmacological studies in rodents and the baboon, Papio papio. Neuropharmacology. 1984;23:525-530.
121. DeSarro GB, DeSarro A. Antagonists of adenosine and alpha-2-adrenoceptors reverse the anticonvulsant effects of tizanidine in DBA/2 mice. Neuropharmacology. 1989;28:211-215.
122. Van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy. A practical guide. Drugs. 1995;49:200-212.
123. Nance PW, Sheremata WA, Lynch G, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol. 1997;54:731-736.
124. Davies J, Johnston SE, Lovering R. Inhibition of DS 103-282 of D-(3H) aspartate release from spinal cord slices. Br J Pharmacol. 1983;78:(Suppl):2P.
125. Palmeri A, Weisendanger M. Concomitant depression of locus coruleus neurons and of flexor reflexes by an alpha 2-adrenergic agonist in rats: A possible mechanism for an alpha 2-mediated muscle relaxation. Neuroscience. 1990;34:177-187.
126. Curtis DR, Leah JD, Peet MJ. Spinal interneuron depression by DS103-282. Br J Pharmacol. 1983;79:9-11.
127. Barbeau H, Richards CL, Bedard PJ. Action of cyproheptadine in spastic paraparetic patients. J Neurol Neurosurg Psychiatry. 1982;45:923-926.
128. Nance P. A comparison of clonidine, cyproheptadine, and baclofen in spastic spinal cord injured patients. J Am Paralegia Soc. 1994;17:151-157.
129. Norman KE, Pepin A, Barbeau H. Effects of drugs on walking after spinal cord injury. Spinal Cord. 1998;36:699-715.
130. Fung J, Stewart JE, Barbeau H. The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects. J Neurol Sci. 1990;100:85-93.
131. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: A quantitative study. Spinal Cord. 1996;35:171-175.
132. Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686-689.
133. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78:521-524.
134. Dunn M, Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia. 1974;12:175.
135. Petro DJ, Ellenberger C. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol. 1981;21(Suppl 8-9): 413S-416S.
136. Malec J, Harvey RF, Cayner JJ: Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil. 1982;63:116-118.
137. Delwaide PJ, Pennisi G. A comparative electrophysiologic study of diazepam and tetrazepam in patients with spasticity. J Neuro Rehab. 1997;11:91-96.
138. Costa JL, Diazgranados JA. Ivermectin for spasticity in spinal cord injury. Lancet. 1994;343:739.
139. Barbeau H, Ladouceur M, Norman KE, Pepin A, Leroux A. Walking after spinal cord injury: Evaluation, treatment, and functional recovery. Arch Phys Med Rehabil. 1999;80:225-235.
140. Stewart JE, Barbeau H, Gauthier S. Modulation of locomotor patterns and spasticity with clonidine in spinal cord injured patients. Can J Neurol Sci. 1991;18:321-332.
141. Barbeau H, Julien C, Rossignol S. The effects of clonidine and yohimbine on locomotion and cutaneous reflexes in the adult chronic spinal cat. Brain Res. 1987;437:83-96.
142. Wainberg M, Barbeau H, Gauthier S. Quantitative assessment of the effect of cyproheptadine on spastic paretic gait: A preliminary study. J Neurol. 1986;233:311-314.
143. Wainberg M, Barbeau H, Gauthier S. The effects of cyproheptadine on locomotion and on spasticity in patients with spinal cord injuries. J Neurol Neurosurg Psychiatry. 1990;53:754-763.
144. Barbeau H, Rossignol S. The effects of seratonergic drugs on the locomotor pattern and on cutaneous reflexes of the adult chronic spinal cat. Brain Res. 1990;514:555-567.
145. Bodine-Fowler S, Allsing S, Botte MJ. Time course of muscle atrophy and recovery following a phenol-induced nerve block. Muscle Nerve. 1996;19:497-504.
146. Katz J, Knott LW, Feldman DJ. Peripheral nerve injections with phenol in the management of spastic patients. Arch Phys Med Rehabil. 1967;48:97-99.
147. Keenan MA, Tomas ES, Stone L, Gersten LM. Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg [Am]. 1990;15:340-346.
148. Botte MJ, Abrams RA, Bodine-Fowler SC. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks. Orthopedics. 1995;18:151-159.
149. Khalili AA, Betts HB. Peripheral nerve block with phenol in the management of spasticity. Indications and complications. JAMA. 1967;200:1155-1157.
150. Moritz U. Phenol blocks of peripheral nerves. Scand J Rehabil Med. 1973;5:160-163.
151. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol. 1971;13:164-173.
152. Petrillo CR, Chu DS, Davis SW. Phenol block of the tibial nerve in the hemiplegic patient. Orthopedics. 1980;3:871-874.
153. Glenn MB. Nerve blocks. In: Glenn MB, Whyte J, eds. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990:227-258.
154. Carpenter EB, Seitz DG. Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol. 1980;22:497-501.
155. O'Hanlan JT, Galford HR, Bosley J. The use of 45 percent alcohol to control spasticity. VA Med Mon. 1969;96:429-436.
156. Gracies JM, Elovic E, Mcguire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl. 1997;6: S61-S91.
157. Walthard KM, Tchicaloff M. Motor points. In: Licht S, ed. Electrodiagnosis and electromyography. Baltimore: Waverly Press, Inc; 1971:113-133.
158. Kaji R, Rothwell JC, Katayama M, et al. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neurol. 1995;38:155-162.
159. Tardieu G, Hariga J, Tardieu C, Gagnard L, Veliu J. Traitement de la spasticite par infiltration d'alcool dilue' qux points moteurs, ou par injectione' epidurale. Rev Neurol. 1964;110:563-566.
160. Eriksson M. Prilocaine reduces injection pain caused by propofol. Acta Anaesthesiol Scand. 1995;39:210-213.
161. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthamology. 1980;87:1044-1049.
162. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46:26-29.
163. Simpson LL. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155-188.
164. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-1746.
165. Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology. 1993;43:1715-1718.
166. Tsui JKC, O'Brien CF. Clinical trials for spasticity. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker Inc.; 1994:522-533.
167. Benecke R. Botulium toxin for spasms and spasticity in the lower extremities. In Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker; 1994:557-565.
168. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am J Phys Med Rehabil. 1993;72:364-368.
169. Dengler R, Neyer U, Wohlfarth K, Bettig U, Janzik HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol. 1992;239:375-378.
170. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch Phys Med Rehabil. 1990;71: 24-26.
171. Al-Khodairy AT, Gobelet C, Rossier AB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients? Spinal Cord. 1998;36:854-858.
172. O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-S180.
173. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve. 1993;16:964-969.
174. Ajax T, Ross MA, Rodnitzky RL. The role of electromyography in guiding botulinum toxin injections for focal dystonia and spasticity. J Neuro Rehabil. 1998;12:1-4.
175. Russman BS, Tilton A, Gormley ME. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl. 1997;6:S181-S193.
176. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997;6:S208-S220.
177. Roggenbuck D, Yablon SA. Safety of high dose botulinum toxin A injection for spasticity in adults [abstract]. Arch Phys Med Rehabil. 1995;76:1069.
178. Abel NA, Smith RA. Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil. 1994;75:54-58.
179. Azouvi P, Mane M, Thiebaut TB, Denys P, Remy-Neris D. Intrathecal baclofen in severe spinal spasticity. N Engl J Med. 1989;320: 1517-1521.
180. Becker W, Letts L. Intrathecal baclofen for adults with spinal spasticity. Can J Neurol Sci. 1995;22:122-129.
181. Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, et al. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg. 1993;78:226-232.
182. Nance PW, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: Therapeutic efficacy and effect on hospital admissions. Can J Neurol Sci. 1995;22:22-29.
183. Penn RD, Kroin JS. Continous intrathecal baclofen for severe spasticity. Lancet. 1985;2:125-127.
184. Parke B, Penn RD, Savoy SM, Corcos D. Functional outcome after delivery of intrathecal baclofen. Arch Phys Med Rehabil. 1989;70:30-32.
185. Loubser PG, Narayan RK, Sandin KJ, Donovan WH, Russel KD. Continuous infusion of intrathecal baclofen: Long-term effects on spasticity in spinal cord injury. Paraplegia. 1991;29:48-64.
186. Nanninga JB, Frost F, Penn R. Effect of intrathecal baclofen on bladder and sphincter function. J Urol. 1989;142:101-105.
187. Denys P, Mane M, Azouvi P, Chartier-Kastler E, Thiebaut JB, Bussel B. Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil. 1998;79:494-496.
188. Muller-Schwefe G, Penn RD. Physostigmine in the treatment of intrathecal baclofen overdose. Report of three cases. J Neurosurg. 1989;71:273-275.
189. Middleton JW, Siddall PJ, Walker S, Molloy AR, Rutkowski SB. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: A case study. Arch Phys Med Rehabil. 1996;77:824-826.
190. Erickson DL, Blacklock JB, Michaelson M, Sperling KB, Lo JN. Control of spasticity by implantable continuous flow morphine pump. Neurosurgery. 1985;16:215-217.